Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Cronos Group Inc (CRON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Cronos Group Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223 (market cap $29.60B), while Cronos Group Inc trades at $3.18 (market cap $1.14B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 26× Cronos Group Inc's market cap, and Cronos Group Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | CRON | |
|---|---|---|
Market Cap | $29.60B | $1.14B |
Sector | Health | Health |
52-Week High | $491.22 | $3.27 |
52-Week Low | $205.48 | $2.30 |
Enterprise Value | $27.56B | $341.13M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
CRON trades at $3.165, up 5.5% with bullish technical signals from moving averages. The company shows strong revenue growth, with Q2 2026 beating expectations with $0.09 EPS versus $0.01 expected, and record quarterly performance. However, profitability remains inconsistent with negative net income in 2025. Analyst sentiment is mixed with 60% hold ratings, reflecting cautious optimism amid competitive pressures.
Outlook is cautiously optimistic with international expansion driving growth, but execution risks and cannabis sector volatility persist. The stock offers growth potential through European market penetration and product innovation, though investors should monitor margin improvements and competitive dynamics closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →
